


Ask a doctor about a prescription for Duphaston
10 mg, coated tablets
Dydrogesterone
Duphaston contains the active substance dydrogesterone.
Duphaston can be used alone or in combination with estrogen. The simultaneous use of estrogen depends on the indication for use.
Duphaston is used to treat:
Normally, the body produces the right amounts of natural progesterone and natural estrogen (another important female hormone) in the right proportions. If the body does not produce enough progesterone, Duphaston supplements this amount and restores balance.
The doctor may prescribe the simultaneous use of estrogen with Duphaston. This depends on the indication for which the medicine is taken.
In some women using HRT, taking only estrogen may cause the uterine lining to grow. This can also occur if the patient has had a hysterectomy and has had endometriosis in the past. Taking dydrogesterone for part of the cycle prevents the uterine lining from growing.
In the case of taking Duphaston simultaneously with estrogen, e.g. as HRT, you should also read the patient information leaflet accompanying the estrogen-containing medicine.
In the case of taking Duphaston due to abnormal bleeding, the doctor will determine the cause of the bleeding before starting treatment.
Usually, the occurrence of unexpected bleeding or spottingis not a cause for concern. This happens especially during the first few months of taking Duphaston.
However, you should contact your doctor immediatelyif the bleeding or spotting:
taking Duphastonif you have any of the following diseases:
If any of the above warnings apply to the patient (or in case of doubts), you should consult a doctor or pharmacist before starting Duphaston. It is especially important to inform the doctor if the disease worsened during pregnancy or during previous hormone therapy. If the disease worsens or recurs while taking Duphaston, the doctor may recommend stopping treatment.
HRT, in addition to its benefits, carries certain risks that the patient and doctor must consider before starting treatment. When taking Duphaston simultaneously with estrogen as HRT, the following information is important. You should also read the patient information leaflet accompanying the estrogen-containing medicine.
There is limited data on the risk of HRT during the onset of menopausal symptoms. The risk is lower in younger women.
This means that in younger women using HRT, the relationship between benefits and risks is better than in older women.
Before starting or re-applying HRT, the doctor will conduct a medical history and family history. The doctor may also order a breast and pelvic exam.
Before and during treatment, the doctor may order screening tests, such as mammography (breast X-ray). The doctor will inform you how often to perform these tests. After starting Duphaston, you should regularly schedule follow-up appointments with your doctor (at least once a year).
In women with an intact uterus taking estrogens for a long time as part of HRT, there is a higher risk of:
Data confirm that taking hormone replacement therapy (HRT) in the form of estrogen and progestogen, or estrogen alone, increases the risk of breast cancer. The additional risk depends on how long the patient takes HRT. This additional risk becomes apparent after about 3 years (1-4) of HRT. After stopping HRT, the additional risk will decrease over time, but the risk may persist for 10 years or more if HRT lasted more than 5 years.
You should:
Ovarian cancer is rare - much rarer than breast cancer. Taking HRT containing only estrogens or a combination of estrogens and progestogens is associated with a slightly increased risk of ovarian cancer.
The risk of ovarian cancer depends on age. For example, in women aged 50-54 who do not take HRT, ovarian cancer will be diagnosed within 5 years in about 2 women out of 2000. In women who took HRT for 5 years, it will occur in about 3 women out of 2000 taking it (i.e. about 1 additional case).
HRT increases the risk of blood clots in the veins. This risk is 3 times higher than in women not taking HRT. The risk is highest in the first year of HRT.
Blood clots are more likely to occur in:
In case of painful leg swelling, sudden chest pain, or difficulty breathing:
You should also inform your doctor or pharmacist about taking medicines that prevent blood clots (anticoagulants), such as warfarin. The doctor will pay special attention to the benefits and risks of HRT.
In case of planned surgery, you should inform your doctor about taking HRT. It may be necessary to stop taking HRT a few weeks before surgery. In some cases, it may be necessary to use other treatment before and after surgery. The doctor will inform you when you can start taking HRT again.
HRT does not prevent heart disease. In women taking estrogen and progesterone as part of HRT, there is a slightly higher likelihood of heart disease than in women not taking HRT. The risk of heart disease increases with age. The number of additional cases of heart disease due to HRT with estrogen and progestogen is very small in healthy women with early menopausal symptoms, but before menopause. The number of additional cases increases with age.
In case of chest pain that radiates to the arm or neck:
Taking HRT in the form of estrogen and progestogen or estrogen alone increases the risk of stroke. This risk is 1.5 times higher than in people not taking HRT. The increased risk in HRT users compared to non-users does not change with age and time since menopause. However, since the risk of stroke is strongly dependent on age, the overall risk of stroke in women taking HRT increases with age.
In case of severe, unexplained headaches or migraines (with or without visual disturbances):
There are no indications for the use of Duphaston in children before their first menstruation. It is not known whether Duphaston is safe and effective in adolescents aged 12-18.
Tell your doctor or pharmacist about all medicines you are currently taking, or have recently taken, and any medicines you plan to take, including those available without a prescription and herbal medicines.
In particular, inform your doctor or pharmacist about taking the following medicines:
Duphaston can be taken with or without food.
In pregnancy, breastfeeding, or if you think you may be pregnant, or plan to become pregnant, consult your doctor before taking this medicine.
There may be an increased risk of hypospadias (a congenital defect of the penis where the urethral opening is in an abnormal location) in children whose mothers took certain progestogens. However, this increased risk has not been conclusively confirmed. So far, there is no evidence that taking dydrogesterone during pregnancy is harmful. More than 10 million women have taken Duphaston during pregnancy.
Do not take Duphaston while breastfeeding. It is not known whether Duphaston passes into breast milk or affects the baby. Studies on other progestogens have shown that a small amount of the medicine passes into the breast milk of nursing mothers.
There is no evidence that dydrogesterone reduces fertility when taken as directed by a doctor.
After taking Duphaston, you may experience slight drowsiness or dizziness. This is more likely to occur during the first few hours after taking the medicine. If you experience these symptoms, do not drive or operate tools or machines.
You should wait and observe how the medicine affects you before deciding to drive or operate tools or machines.
If you have been informed by your doctor that you have an intolerance to some sugars, you should consult your doctor before taking this medicine. This applies to rare hereditary diseases that affect the body's ability to use lactose, such as "lactase deficiency" or "glucose-galactose malabsorption syndrome".
Duphaston should always be taken as directed by your doctor. If you have any doubts, consult your doctor or pharmacist. The doctor will adjust the dose according to your needs.
The number of tablets to take and the days on which the medicine is taken depend on the indication. If the patient is still menstruating, day 1 of the cycle is the day bleeding starts. If the patient no longer has natural periods, the doctor will determine the first day of the cycle and decide when to start taking the tablets.
It is unlikely that taking too many Duphaston tablets will be harmful. There is no need to treat this condition. In case of doubts or if you experience any worrying symptoms, consult your doctor.
Do not stop taking Duphaston without consulting your doctor.
Like all medicines, Duphaston can cause side effects, although not everybody gets them. The following side effects may occur while taking the medicine:
Frequent(affects less than 1 in 10 patients)
Uncommon(affects less than 1 in 100 patients)
Rare(affects less than 1 in 1000 patients)
In younger patients, similar side effects are expected as those that occurred in adults.
When taking Duphaston with estrogen, you should also read the patient information leaflet accompanying the estrogen-containing medicine. For more information on the following side effects, see the "Important information before taking Duphaston" section.
Other side effects that occur when taking Duphaston with estrogen include:
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301; Fax: +48 22 49 21 309; website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
There are no special storage instructions for the medicine.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Round, biconvex, divisible coated tablets, white in color, with the inscription "155" on both sides of the score line, on one side of the tablet.
20 tablets in a PVC/Al or PVC/PVDC/Al blister pack, in a cardboard box.
Theramex Ireland Limited
3rd Floor, Kilmore House
Spencer Dock, Park Lane
Dublin 1, D01 YE64
Ireland
Abbott Biologicals B.V.
Veerweg 12
8121 AA Olst, Netherlands
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Duphaston – subject to medical assessment and local rules.